J&J Medtech Execs Say Strategic Merit, Not Size, Matters in M&A

Johnson & Johnson remains focused on both internal innovation as well as merger and acquisition opportunities. That includes the company's medtech business.

During the company's first-quarter 2022 earnings call on Tuesday, Joe Wolk, executive VP and CFO at Johnson & Johnson, said the company increased R&D investment in the first quarter by about 9% compared to the same period last year.